Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results

Maniatis AK, Casella SJ, Nemchenko Um, Hofman PL,Paul Saenger, Chertock ED, Aghajanova EM, M Korpal-Szczyrska,E Vlachopapadopoulou,Oleg Malievsky,Tetyana Chaychenko,Marco Cappa,W Song, M. Antonieta Guzmán M., Mygind PH, Smith Ar, Chessler SD, Komirenko AS,Michael Beckert, Shu AD, Thornton PS

Yearbook of pediatric endocrinology（2023）

引用 4|浏览4

暂无评分

摘要

Brief summary: This open-label extension trial enrolled all subjects completing the two previous phase 3 Lonapegsomatropin trials, heiGHt and fliGHt. The results confirm the efficacy of this LAGH formulation in improving height SDS, without major adverse events.

查看译文

关键词

lonapegsomatropin,growth hormone deficiency,efficacy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要